Previous close | 140.78 |
Open | 140.78 |
Bid | 151.90 |
Ask | 154.20 |
Strike | 230.00 |
Expiry date | 2025-01-17 |
Day's range | 140.78 - 140.78 |
Contract range | N/A |
Volume | |
Open interest | 4 |
Vertex Pharmaceuticals beat first-quarter sales and earnings forecasts, but shares were little moved on the reiterated guidance.
Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Sales from Vertex's top-selling CF drug Trikafta, also sold as Kaftrio in some markets, rose more than 18% from a year earlier to $2.48 billion in the quarter, beating analysts' expectations of $2.38 billion.
BOSTON, May 06, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance.